Assessment of tissue fibrosis in skin biopsies from patients with systemic sclerosis employing confocal laser scanning microscopy: An objective outcome measure for clinical trials?

Rheumatology

Volumn 49, Issue 6, 2010, Pages 1069-1075

  Busquets, Joanna ^a   Del Galdo, Francesco ^a   Kissin, Eugene Y ^b   Jimenez, Sergio A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trials outcome measure; Confocal laser scanning microscopy; Fibrosis; Scleroderma; Skin collagen; Systemic sclerosis

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; FIBRONECTIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER PROGRAM; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; FEMALE; FLUORESCENCE ANALYSIS; FOLLOW UP; FOREARM; HUMAN; IMAGE ANALYSIS; MALE; PRIORITY JOURNAL; REFERENCE VALUE; SKIN BIOPSY; SKIN FIBROSIS; SKINFOLD THICKNESS; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME;

ADULT; BIOPSY; CASE-CONTROL STUDIES; CLINICAL TRIALS AS TOPIC; COLLAGEN; FEMALE; FIBROSIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MICROSCOPY, CONFOCAL; MIDDLE AGED; MYCOPHENOLIC ACID; SCLERODERMA, SYSTEMIC; SKIN; STATISTICS AS TOPIC;

EID: 77953505288     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq024     Document Type: Article

References (32)

1. Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004;140:37-50.
2. Varga JA, Trojanowska M. Fibrosis in systemic sclerosis. Rheum Dis Clin N Am 2008;34:115-43.
3. Rodnan GP. Progressive systemic sclerosis: clinical features and pathogenesis of cutaneous involvement (scleroderma). Clin Rheum 1988;18:1-13.
4. Jimenez SA. Cellular immune dysfunction and the pathogenesis of scleroderma. Semin Arthritis Rheum 1983;13:104-13.
5. Steen VD, Medsger TA Jr. Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 2001;44:2828-35.
6. Clements PJ, Hurwitz EL, Wong WK et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis. Arthritis Rheum 2000;43:2445-54.
7. Medsger TA, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W. Assessment of disease severity and prognosis. Clin Exp Rheumatol 2003;21:S42-6.
8. Seibold JR, McCloskey DA. Skin involvement as a relevant outcome measure in clinical trials of systemic sclerosis. Curr Opin Rheumatol 1997;9:571-5.
9. Rodnan GP, Lipinski E, Luksick J. Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum 1979;22: 130-40.
10. Kahaleh MB, Sultany GL, Smith EA, Huffstutter JE, Loadholt CB, LeRoy EC. A modified scleroderma skin scoring method. Clin Exp Rheumatol 1986;4:367-9.
11. Clements P, Lachenbruch P, Seibold J et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5.
12. Kissin EY, Schiller AM, Gelbard RB et al. Durometry for the assessment of skin disease in systemic sclerosis. Arthritis Rheum 2006;55:603-9.
13. Kuwahara Y, Shima Y, Shirayama D et al. Quantification of hardness, elasticity and viscosity of the skin of patients with systemic sclerosis using a novel sensing device (Vesmeter): a proposal for a new outcome measurement procedure. Rheumatology 2008;47:1018-24.
14. Allanore Y, Borderie D, Lemaréchal H, Cherruau B, Ekindjian OG, Kahan A. Correlation of serum collagen I carboxyterminal telopeptide concentrations with cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol 2003;30:68-73.
15. Black CM, McWhirter A, Harrison NK, Kirk JM, Laurent GJ. Serum type III procollagen peptide concentrations in systemic sclerosis and Raynaud's phenomenon: relationship to disease activity and duration. Br J Rheumatol 1989;28:98-103.
16. Becvár R, Hulejová H, Braun M, Stork J. Collagen degradation products and proinflammatory cytokines in systemic and localized scleroderma. Folia Biol 2007;53: 66-8.
17. Nagy Z, Czirják L. Increased levels of amino terminal propeptide of type III procollagen are an unfavorable predictor of survival in systemic sclerosis. Clin Exp Rheumatol 2005;23:165-72.
18. Dodge GR, Hawkins D, Boesier E, Sakai L, Jimenez SA. Production of cartilage oligomeric matrix protein (COMP) by cultured human dermal and synovial fibroblasts. Osteoarthritis Cartilage 1998;6:435-40.
19. Hesselstrand R, Kassner A, Heinegård D, Saxne T. COMP: a candidate molecule in the pathogenesis of systemic sclerosis with a potential as a disease marker. Ann Rheum Dis 2008;67:1242-8.
20. Farina G, Lemaire R, Korn JH, Widom RL. Cartilage oligomeric matrix protein is overexpressed by scleroderma dermal fibroblasts. Matrix Biol 2006;25: 213-22.
21. Farina G, Lemaire R, Pancari P, Bayle J, Widom RL, Lafyatis R. Cartilage oligomeric matrix protein expression in systemic sclerosis reveals heterogeneity of dermal fibroblast responses to transforming growth factor beta. Ann Rheum Dis 2009;68:435-41.
22. Kissin EY, Merkel PA, Lafyatis R. Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis. Arthritis Rheum 2006;54:3655-60.
23. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
24. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
25. Morath C, Schwenger V, Beimler J et al. Antifibrotic actions of mycophenolic acid. Clin Transplant 2006;17: 25-9.
26. Roos N, Poulalhon N, Farge D, Madelaine I, Mauviel A, Verrecchia F. In vitro evidence for a direct antifibrotic role 1074 www.rheumatology.oxfordjournals.org of the immunosuppressive drug mycophenolate mofetil. J Pharmacol Exp Ther 2007;321:583-9.
27. Gerbino AJ, Goss CH, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 2008;133:455-60.
28. Zamora AC, Wolters PJ, Collard HR et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med 2008; 102:150-5.
29. Plastiras SC, Vlachoyiannopoulos PG, Tzelepis GE. Mycophenolate mofetil for interstitial lung disease in scleroderma. Rheumatology 2006;45:1572.
30. Liossis SN, Bounas A, Andonopoulos AP. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology 2006;45: 1005-8.
31. Nihtyanova SI, Brough GM, Black CM, Denton CP. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis-a retrospective analysis. Rheumatology 2007; 46:442-5.
32. Derk CT, Grace E, Shenin M, Naik M, Schulz S, Xiong W. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology 2009;48:1595-9.